TY - JOUR
T1 - Ceftazidime pulmonary epithelial lining fluid concentrations during continuous and intermittent infusion in swine
AU - Hanes, Scott D.
AU - Wood, G. Christopher
AU - Mandrell, Timothy D.
AU - Gades, Naomi M.
PY - 2001/12/1
Y1 - 2001/12/1
N2 - The pharmacokinetics and pharmacodynamics (T>MIC) of ceftazidime in the plasma and pulmonary epithelial lining fluid (ELF) were compared following intermittent (IC) and continuous ceftazidime (CC) infusion (60 mg/kg/d) in nine crossbred male intact pigs. The ceftazidime plasma half-life, volume of distribution, clearance, and area under the plasma concentration-time curve were similar between the IC and CC regimens. Ceftazidime area under the ELF concentration-time curve were 29.6% and 23.4% of the area under the plasma concentration-time curve for the IC and CC regimens, respectively. The ceftazidime half-life in the ELF was approximately two-fold longer compared to the plasma half-life. This suggests that the penetration of ceftazidime into the ELF is membrane-limited and may not display compartmental pharmacokinetic characteristics. Using T>MIC as a surrogate marker of efficacy, ceftazidime's limited ELF penetration may hinder pharmacodynamic optimization against less susceptible gram-negative bacteria causing pneumonia.
AB - The pharmacokinetics and pharmacodynamics (T>MIC) of ceftazidime in the plasma and pulmonary epithelial lining fluid (ELF) were compared following intermittent (IC) and continuous ceftazidime (CC) infusion (60 mg/kg/d) in nine crossbred male intact pigs. The ceftazidime plasma half-life, volume of distribution, clearance, and area under the plasma concentration-time curve were similar between the IC and CC regimens. Ceftazidime area under the ELF concentration-time curve were 29.6% and 23.4% of the area under the plasma concentration-time curve for the IC and CC regimens, respectively. The ceftazidime half-life in the ELF was approximately two-fold longer compared to the plasma half-life. This suggests that the penetration of ceftazidime into the ELF is membrane-limited and may not display compartmental pharmacokinetic characteristics. Using T>MIC as a surrogate marker of efficacy, ceftazidime's limited ELF penetration may hinder pharmacodynamic optimization against less susceptible gram-negative bacteria causing pneumonia.
KW - Administrations and dosage
KW - Alveolar lining fluid
KW - Analysis
KW - Bronchoalveolar lavage
KW - Ceftazidime
KW - Pharmacokinetics
KW - Swine
UR - http://www.scopus.com/inward/record.url?scp=0035685940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035685940&partnerID=8YFLogxK
U2 - 10.1300/J100v04n04_03
DO - 10.1300/J100v04n04_03
M3 - Article
AN - SCOPUS:0035685940
SN - 1068-7777
VL - 4
SP - 29
EP - 41
JO - Journal of Infectious Disease Pharmacotherapy
JF - Journal of Infectious Disease Pharmacotherapy
IS - 4
ER -